Literature DB >> 17961074

Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization.

Mikayel Mkrtichyan1, Anahit Ghochikyan, Nina Movsesyan, Adrine Karapetyan, Gayane Begoyan, Jianmei Yu, Gregory M Glenn, Ted M Ross, Michael G Agadjanyan, David H Cribbs.   

Abstract

The focus of this report is on the development of an improved DNA immunization protocol, which takes advantage of the strengths of DNA immunization, as well as those associated with adjuvant delivered by transcutaneous immunostimulatory (IS) patches. Because transcutaneous delivery of adjuvants to the skin at the vaccination site has been shown to amplify the immune response to protein antigens, we hypothesized that the same IS patch when placed on the skin at the site of DNA injection could further enhance the immune response to a DNA influenza vaccine. We have combined an influenza DNA vaccine, hemagglutinin fused with three copies of complement C3d, to enhance uptake and antigen presentation, with an IS patch containing heat-labile enterotoxin from Escherichia coli. Coadministration of a potent adjuvant in IS patches placed on the skin at the site of DNA vaccination dramatically amplifies anti-influenza antibody immune response. Supplementing DNA vaccines with IS patches may be a particularly valuable strategy because DNA vaccines can be rapidly modified in response to mutations in pathogens, and individuals with compromised immune systems such as transplant patients and the elderly will benefit from the enhanced antibody response induced by the IS patches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17961074      PMCID: PMC2478559          DOI: 10.1089/dna.2007.0639

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  33 in total

1.  Skin immunization made possible by cholera toxin.

Authors:  G M Glenn; M Rao; G R Matyas; C R Alving
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

Review 2.  Genetic immunization: a new era in vaccines and immune therapeutics.

Authors:  M Chattergoon; J Boyer; D B Weiner
Journal:  FASEB J       Date:  1997-08       Impact factor: 5.191

3.  DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs.

Authors:  H L Robinson; C A Boyle; D M Feltquate; M J Morin; J C Santoro; R G Webster
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

4.  Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen.

Authors:  J M Ahearn; M B Fischer; D Croix; S Goerg; M Ma; J Xia; X Zhou; R G Howard; T L Rothstein; M C Carroll
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

Review 5.  Lymphokine control of in vivo immunoglobulin isotype selection.

Authors:  F D Finkelman; J Holmes; I M Katona; J F Urban; M P Beckmann; L S Park; K A Schooley; R L Coffman; T R Mosmann; W E Paul
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

6.  Cholera toxin prevents Th1-mediated autoimmune disease by inducing immune deviation.

Authors:  Shao-Bo Su; Phyllis B Silver; Peng Wang; Chi-Chao Chan; Rachel R Caspi
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

7.  Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene.

Authors:  Anahit Ghochikyan; Vitaly Vasilevko; Irina Petrushina; Nina Movsesyan; Davit Babikyan; Wenqiang Tian; Nadya Sadzikava; Ted M Ross; Elizabeth Head; David H Cribbs; Michael G Agadjanyan
Journal:  Eur J Immunol       Date:  2003-12       Impact factor: 5.532

8.  C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.

Authors:  P W Dempsey; M E Allison; S Akkaraju; C C Goodnow; D T Fearon
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

Review 9.  Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent.

Authors:  Ed C Lavelle; Andrew Jarnicki; Edel McNeela; Michelle E Armstrong; Sarah C Higgins; Olive Leavy; Kingston H G Mills
Journal:  J Leukoc Biol       Date:  2004-01-02       Impact factor: 4.962

10.  Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice.

Authors:  Mimi Guebre-Xabier; Scott A Hammond; Larry R Ellingsworth; Gregory M Glenn
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more
  7 in total

1.  Factors that may impact on immunosenescence: an appraisal.

Authors:  Joseph Ongrádi; Valéria Kövesdi
Journal:  Immun Ageing       Date:  2010-06-14       Impact factor: 6.400

2.  Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Authors:  Nitin Bhardwaj; Mark T Heise; Ted M Ross
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

Review 3.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

4.  Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Armine Hovakimyan; Irina Petrushina; Jianmei Yu; David Flyer; Peter Juul Madsen; Lars Ostergaard Pedersen; David H Cribbs; Michael G Agadjanyan
Journal:  J Neuroimmunol       Date:  2014-01-15       Impact factor: 3.478

5.  Challenges for vaccination in the elderly.

Authors:  Richard Aspinall; Giuseppe Del Giudice; Rita B Effros; Beatrix Grubeck-Loebenstein; Suryaprakash Sambhara
Journal:  Immun Ageing       Date:  2007-12-11       Impact factor: 6.400

Review 6.  Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?

Authors:  Babak Jalilian; Stig Hill Christiansen; Halldór Bjarki Einarsson; Mehdi Rasoli Pirozyan; Eskild Petersen; Thomas Vorup-Jensen
Journal:  Mol Cell Ther       Date:  2013-11-06

7.  Lower-Sized Chitosan Nanocapsules for Transcutaneous Antigen Delivery.

Authors:  Juan I Bussio; Carla Molina-Perea; José Vicente González-Aramundiz
Journal:  Nanomaterials (Basel)       Date:  2018-08-26       Impact factor: 5.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.